Prostatic NeoplasmsEPICAP-QALYNCT02854982
Impact on Quality of Life 3 Years After Diagnosis of Prostate Cancer
An observational study of Prostatic Neoplasms and Quality of Life, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
Trial summary
To study the quality of life of patients with prostate cancer at a distance from their care at a time when they are supposed to have taken a "normal" life and compared to subjects without cancer prostate of the same age. Read more about this study
- Who is it for?
- Ages Up to 75 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Prostatic Neoplasms, Quality of Life
- What is being tested?
- therapeutic management of the prostate Cancer as usual
- Type of treatment
- Surgery or procedure
- How many people
- 900 participants
- Where
- 1 siteFrance
- Study dates
- 1 Sep 2015to 31 Jul 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 75 years
- Men only
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Target population: incident cases of prostate cancer
Who may be able to join
- prostate cancer diagnosed from 1 December 2011 to 31 December 2014
- under 75 and residing in the Hérault department at diagnosis
- recruited in the EPICAP study
- controls (without prostate cancer) recruited in the EPICAP study
- matched to cases on age (5 years)
- residing in the Hérault department
Who cannot join
- having relapsed in the range
- non-exposed group:
- diagnosis of prostate cancer set in the range
Trial locations and contacts
1 site in 1 country.
About this study
To study the quality of life of patients with prostate cancer at a distance from their care at a time when they are supposed to have taken a "normal" life and compared to subjects without cancer prostate of the same age.
- Conditions
- Prostatic Neoplasms, Quality of Life
- Being tested
- therapeutic management of the prostate Cancer as usual
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
therapeutic management of the prostate Cancer as usualProcedure or surgery
| Study group | Role | What they receive |
|---|---|---|
| Prostate Cancer | Group drawn of the case group of the case control study, entitled EPICAP Receives: Procedure: therapeutic management of the prostate Cancer as usual | |
| No Prostate Cancer | Group drawn of the control group of the case control study, entitled EPICAP |
What is being measured
The primary outcome is the main question the study is designed to answer.
EORTC Quality of Life Questionnaire - Core 30 Score (EORTC QLQ-C30 Score)
Measured: 3 years from diagnosis for cases of prostate cancer and from recruitment for controls
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Aug 2016 (estimated)
- Study start1 Sep 2015
- Primary completion31 Jul 2017
- Study completion31 Jul 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Prostatic NeoplasmsStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NīmesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 900 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02854982
- Sponsor's protocol ID
- LIGUE/2014/NH-001
- Acronym
- EPICAP-QALY
- Status last verified
- Aug 2018
- First submitted
- 1 Aug 2016
- Last updated
- 22 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Publications
Houede N, Rebillard X, Bouvet S, Kabani S, Fabbro-Peray P, Tretarre B, Menegaux F. Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study. BMC Cancer. 2020 Aug 12;20(1):757. doi: 10.1186/s12885-020-07244-y.
PubMed 32787797
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact on Quality of Life 3 Years After Diagnosis of Prostate Cancer
- ClinicalTrials.gov ID
- NCT02854982
- Acronym / sponsor ID
- EPICAP-QALY / LIGUE/2014/NH-001
- Conditions
- Prostatic Neoplasms, Quality of Life
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 900 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire de NīmesUniversity, hospital or other
- Study start
- 1 Sep 2015 (actual)
- Primary completion
- 31 Jul 2017 (actual)
- Study completion
- 31 Jul 2017 (actual)
- First posted
- 4 Aug 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To study the quality of life of patients with prostate cancer at a distance from their care at a time when they are supposed to have taken a "normal" life and compared to subjects without cancer prostate of the same age.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Prostate Cancer | – | Procedure: therapeutic management of the prostate Cancer as usualGroup drawn of the case group of the case control study, entitled EPICAP |
| No Prostate Cancer | – | –Group drawn of the control group of the case control study, entitled EPICAP |
Who may qualify
- Ages
- Up to 75 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Target population: incident cases of prostate cancer
Key inclusion criteria (6 listed)
- prostate cancer diagnosed from 1 December 2011 to 31 December 2014
- under 75 and residing in the Hérault department at diagnosis
- recruited in the EPICAP study
- controls (without prostate cancer) recruited in the EPICAP study
- matched to cases on age (5 years)
Key exclusion criteria (3 listed)
- having relapsed in the range
- non-exposed group:
- diagnosis of prostate cancer set in the range
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| therapeutic management of the prostate Cancer as usual | Procedure or surgery | Prostate Cancer |
Primary outcome
EORTC Quality of Life Questionnaire - Core 30 Score (EORTC QLQ-C30 Score)
Time frame: 3 years from diagnosis for cases of prostate cancer and from recruitment for controls
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2026.
- Results publication: PubMed 32787797Houede N, Rebillard X, Bouvet S, Kabani S, Fabbro-Peray P, Tretarre B, Menegaux F. Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study. BMC Cancer. 2020 Aug 12;20(1):757. doi: 10.1186/s12885-020-07244-y.
- Individual participant dataSharing planned: Undecided
Related trials for Prostatic Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prostatic Neoplasms and Quality of Life, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
EORTC Quality of Life Questionnaire - Core 30 Score (EORTC QLQ-C30 Score) (time frame: 3 years from diagnosis for cases of prostate cancer and from recruitment for controls). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02854982, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.